Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02913612 · ClinicalTrials.gov registry record · Phase 2

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

A Phase 2 study, sponsored by Kanecia Obie Zimmerman.

Completed
Registry status
Phase 2
Development phase
105
Enrollment target

NCT02913612: Completed Phase 2 study, sponsored by Kanecia Obie Zimmerman.

NCT02913612 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 105 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02913612, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.

COMPLETED
Registry status
Phase 2
Development phase
105 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.

Primary Outcome

The VAS-volume is a 100 mm scale used to independently grade hemangioma volume. -100 indicates hemangioma has doubled in size, 0 indicates no change, and +100 indicates complete shrinkage. Partial response is defined as \>20% and up to 80% reduction in volumetric size of hemangioma.

Interventions

  • DRUG 0.25% Timolol Maleate Gel Forming Solution
  • DRUG 0.5% Timolol Maleate Gel Forming Solution

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2017-05-05
Est. Completion 2020-10-20
Phase Phase 2
Kanecia Obie Zimmerman

7 total trials

What the finished NCT02913612 record still lists

NCT02913612 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (21% lower).

The record links to 0 conditions, and to 2 interventions - of which 0.25% Timolol Maleate Gel Forming Solution is the first listed.

NCT02913612 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02913612 about?

NCT02913612 is a clinical study titled "Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)". The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.

What is the current status of trial NCT02913612?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2017-05-05. Estimated completion is 2020-10-20.

What interventions are being tested in trial NCT02913612?

The interventions under investigation include: 0.25% Timolol Maleate Gel Forming Solution (DRUG), 0.5% Timolol Maleate Gel Forming Solution (DRUG).

Who is sponsoring clinical trial NCT02913612?

This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02913612's enrollment target sits among peer trials

105 650th of 2000 higher than 1,341 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02913612, the US trial registry maintained by the National Library of Medicine. NCT02913612 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.